Vertex Pharmaceuticals director proposes $548K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vertex Pharmaceuticals (VRTX) director Nancy A. Thornberry reported a proposed sale of 1,000 common shares, with an aggregate market value of $547,860.00 and an approximate sale date of November 16, 2026.
The notice lists the shares as acquired through restricted-stock vesting: 499 on December 5, 2024, and 501 on May 1, 2025. It gives August 15, 2026, as the date of plan adoption or instruction if relying on Rule 10b5-1.
Key Figures
Key Terms
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.